Effects of Chinese herbal medicine Yiqi Huaju Formula on hypertensive patients with metabolic syndrome: A randomized, placebo-controlled trial

Journal of Chinese Integrative Medicine

Volumn 11, Issue 3, 2013, Pages 184-194

  Chen, Yi ^a   Fu, De yu ^b   Chen, Yu ^b   He, Yan ming ^b   Fu, Xiao dong ^a   Xu, Yan qiu ^b   Liu, Yi ^a   Feng, Xiaotao ^a   Zhang, Teng ^b   Wang, Wen jian ^a,b  

^a FUDAN UNIVERSITY   (China)

^b SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

Author keywords

Ambulatory blood pressure monitoring; Blood pressure variability; Chinese herbal; Drugs; Hypertension; Investigational; Metabolic syndrome; Therapies

Indexed keywords

AMLODIPINE; CHOLESTEROL; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLANT MEDICINAL PRODUCT; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VALSARTAN; YIQI HUAJU;

ADULT; AGED; ANTHROPOMETRIC PARAMETERS; ARTICLE; BLOOD PRESSURE VARIABILITY; CARDIOVASCULAR RISK; CHINESE MEDICINE; CLINICAL ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; HYPERTENSION; INSULIN RESISTANCE; MALE; METABOLIC SYNDROME X; PREVALENCE; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR;

EID: 84878659211     PISSN: 16721977     EISSN: None     Source Type: Journal    
DOI: 10.3736/jintegrmed2013031     Document Type: Article

References (36)

1. Scholze J, Alegria E, Ferri C, Langham S, Stevens W, Jeffries D, Uhl-Hochgraeber K. Epidemiological and economic burden of metabolic syndrome and its consequences in patients with hypertension in Germany, Spain and Italy; a prevalence-based model. BMC Public Health. 2010; 10: 529.
2. Andreadis EA, Tsourous GI, Tzavara CK, Georgiopoulos DX, Katsanou PM, Marakomichelakis GE, Diamantopoulos EJ. Metabolic syndrome and incident cardiovascular morbidity and mortality in a Mediterranean hypertensive population. Am J Hypertens. 2007; 20(5): 558-564.
3. Schillaci G, Pirro M, Vaudo G, Gemelli F, Marchesi S, Porcellati C, Mannarino E. Prognostic value of the metabolic syndrome in essential hypertension. J Am Coll Cardiol. 2004; 43(10): 1817-1822.
4. Obesity in Asia Collaboration. Is central obesity a better discriminator of the risk of hypertension than body mass index in ethnically diverse populations? J Hypertens. 2008; 26(2): 169-177.
5. He CY, Wang WJ, Li B, Xu DS, Chen WH, Ying J, He YM. Clinical research of Yiqi Sanju Formula in treating central obese men at high risk of metabolic syndrome. J Chin Integr Med. 2007; 5(3): 263-267. Chinese with abstract in English.
6. Lou SY, Liu Y, Ma YY, Chen HY, Chen WH, Ying J, He YM, Wang WJ. Effects of Yiqi Sanju Formula on non alcoholic fatty liver disease: a randomized controlled trial. J Chin Integr Med. 2008; 6(8): 793-798. Chinese with abstract in English.
7. Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Collaborative Research Group. Diuretic versus alpha-blocker as first-step antihypertensive therapy: final results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Hypertension. 2003; 42(3): 239-246.
8. Joint Committee for Developing Chinese Guidelines on Prevention and Treatment of Dyslipidemia in Adults. Chinese guidelines on prevention and treatment of dyslipidemia in adults. Zhonghua Xin Xue Guan Bing Za Zhi. 2007; 35(5): 390-419. Chinese.
9. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ; Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003; 42(6): 1206-1252.
10. Bianchi C, Penno G, Daniele G, Benzi L, Del Prato S, Miccoli R. Optimizing management of metabolic syndrome to reduce risk: focus on life-style. Intern Emerg Med. 2008; 3(2): 87-98.
11. Zhang X, Sun Z, Zhang X, Zheng L, Li J, Liu S, Xu C, Li J, Zhao F, Hu D, Sun Y. Prevalence of metabolic syndrome in Han and Mongolian rural population with hypertension. J Int Med Res. 2007; 35(5): 597-599.
12. Cheung BM, Wat NM, Man YB, Tam S, Cheng CH, Leung GM, Woo J, Janus ED, Lau CP, Lam TH, Lam KS. Relationship between the metabolic syndrome and the development of hypertension in the Hong Kong Cardiovascular Risk Factor Prevalence Study-2 (CRISPS2). Am J Hypertens. 2008; 21(1): 17-22.
13. Ho JS, Cannaday JJ, Barlow CE, Mitchell TL, Cooper KH, FitzGerald SJ. Relation of the number of metabolic syndrome risk factors with all-cause and cardiovascular mortality. Am J Cardiol. 2008; 102(6): 689-692.
14. Ong KL, Cheung BM, Man YB, Lau CP, Lam KS. Prevalence, awareness, treatment, and control of hypertension among United States adults 1999-2004. Hypertension. 2007; 49(1): 69-75.
15. Li W, Lu WL, Wang Y, Li YL, Sun YM, Huang GW, Wang Z, Wang JH. Association between blood pressure control and risk factor in community hypertensive patients. Zhongguo Gong Gong Wei Sheng. 2012; 28(2): 154-156. Chinese with abstract in English.
16. Wang WJ, Liu Y. Differentiation on "spleen-deficiency resulting in obstacle of transport" and "spleen-deficiency resulting in obstacle of transformation". Shanghai Zhong Yi Yao Da Xue Xue Bao. 2013; 27(1): 8-10. Chinese with abstract in English.
17. Liu Y, Wang WJ, Chen WH, Yin J. Effects of Astragalus polysaccharides on proliferation and differentiation of 3T3-L1 preadipocytes. J Chin Integr Med. 2007; 5(4): 421-426. Chinese with abstract in English.
18. He YM, Wang WJ, Chen WH, Ying J. Effects of Pollen Typhae total flavones on mRNA expressions of peroxisome proliferator-activated receptors in 3T3-L1 adipocytes. J Chin Integr Med. 2008; 6(9): 939-941. Chinese with abstract in English.
19. Liu Y, Lou SY, He YM. Effects of berberine on cell proliferation, peroxisome proliferation activated receptor gamma, CAAT/ enhancer binding protein mRNA and protein expression in 3T3-L1 pre-adipocytes. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2008; 28(11): 1005-1009. Chinese with abstract in English.
20. Rothwell PM, Howard SC, Dolan E, O'Brien E, Dobson JE, Dahlöf B, Sever PS, Poulter NR. Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension. Lancet. 2010; 375(9718): 895-905.
21. Tatasciore A, Renda G, Zimarino M, Soccio M, Bilo G, Parati G, Schillaci G, De Caterina R. Awake systolic blood pressure variability correlates with target-organ damage in hypertensive subjects. Hypertension. 2007; 50(2): 325-332.
22. Parati G, Pomidossi G, Albini F, Malaspina D, Mancia G. Relationship of 24-hour blood pressure mean and variability to severity of target-organ damage in hypertension. J Hypertens. 1987; 5(1): 93-98.
23. Ievleva GI, Teslia EF, Biktimirova DM, Kiklevich AV, Erdakova TK. Parameters of 24-hour arterial pressure in patients with metabolic syndrome. Klin Med (Mosk). 2009; 87(6): 15-18. Russian.
24. Dahlöf B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J; ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005; 366(9489): 895-906.
25. Aalbers J. Reduced blood pressure variability in ASCOTBPLA trial favours use of amlodipine/perindopril combination to reduce stroke risk. Cardiovasc J Afr. 2010; 21(2): 115.
26. Webb AJ, Fischer U, Mehta Z, Rothwell PM. Effects of antihypertensive-drug class on interindividual variation in blood pressure and risk of stroke: a systematic review and meta-analysis. Lancet. 2010; 375(9718): 906-915.
27. Clement DL, De Buyzere M, Duprez DD. Influence of drugs on blood pressure variability. J Hypertens Suppl. 1994; 12(8): S49-S53.
28. Mancia G, Casadel R, Mutti E, Trazzi S, Parati G. Ambulatory blood pressure monitoring in the evaluation of antihypertensive treatment. Am J Med. 1989; 87(6B): 64S-69S.
29. Mulè G, Nardi E, Andronico G, Cottone S, Raspanti F, Piazza G, Volpe V, Ferrara D, Cerasola G. Relationships between 24 h blood pressure load and target organ damage in patients with mild-to-moderate essential hypertension. Blood Press Monit. 2001; 6(3): 115-123.
30. Falqui V, Viazzi F, Leoncini G, Ratto E, Parodi A, Conti N, Tomolillo C, Deferrari G, Pontremoli R. Blood pressure load, vascular permeability and target organ damage in primary hypertension. J Nephrol. 2007; 20(Suppl 12): S63
31. Mancia G, Di Rienzo M, Parati G. Ambulatory blood pressure monitoring use in hypertension research and clinical practice. Hypertension. 1993; 21(4): 510-524.
32. Chen Y, Wang WJ. Relationships between insulin resistant and hypertension and traditional Chinese medicine intervention. J Chin Integr Med. 2010; 8(12): 1114-1118. Chinese with abstract in English.
33. Miura Y, Matsui H. Triphenyltin impairs a protein kinase A (PKA)-dependent increase of cytosolic Na+ and Ca2+ and PKA-independent increase of cytosolic Ca2+ associated with insulin secretion in hamster pancreatic beta-cells. Toxicol Appl Pharmacol. 2006; 216(3): 363-372.
34. Sievers C, Schneider HJ, Stalla GK. Insulin-like growth factor-1 in plasma and brain: regulation in health and disease. Front Biosci. 2008; 13: 85-99.
35. Usukura M, Zhu A, Yoneda T, Karashima S, Yagi K, Yamagishi M, Takeda Y. Effects of a high-salt diet on adipocyte glucocorticoid receptor and 11-beta hydroxysteroid dehydrogenase 1 in salt-sensitive hypertensive rats. Steroids. 2009; 74(12): 978-982.
36. Wang XL, Zhang L, Youker K, Zhang MX, Wang J, LeMaire SA, Coselli JS, Shen YH. Free fatty acids inhibit insulin signaling-stimulated endothelial nitric oxide synthase activation through upregulating PTEN or inhibiting Akt kinase. Diabetes. 2006; 55(8): 2301-2310.